Neurology Research Center, Department of Neurology, Kerman University of Medical Sciences, Kerman, Iran,
Inflammation. 2014 Apr;37(2):604-10. doi: 10.1007/s10753-013-9775-z.
Chemokines play a major role in autoimmune diseases such as multiple sclerosis (MS). Gender also affects the susceptibility and course of MS. The aim of this study was to investigate the serum levels of the macrophage-derived chemokine (CCL22) in women and men patients with MS. Blood samples were collected from 135 healthy subjects (35 men and 100 women) and 135 MS patients (29 men and 136 women; 47 newly diagnosed and 88 treated patients and have relapsing-remitting (RRMS; n = 65), secondary progressive (SPMS; n = 37), primary progressive (PPMS; n = 19), or progressive relapsing (PRMS; n = 14) patterns). The serum levels of CCL22 were measured by ELISA. The difference of the mean serum levels of CCL22 between the newly diagnosed MS men and healthy men was not significant, but in newly diagnosed MS women, the mean serum levels of CCL22 were significantly lower than those in treated MS women and healthy women (P < 0.006 and P < 0.0001, respectively). The differences of the mean CCL22 levels between men patients with different treatment programs were not significant, but the mean CCL22 levels were significantly higher in women treated with interferon-β or the combination of interferon-β plus methylprednisolone as compared to untreated women patients (P < 0.01 and P < 0.05, respectively). The CCL22 levels were also significantly higher in women with RRMS and PRMS patterns in comparison to healthy women (P < 0.05 and P < 0.01, respectively). These results showed lower levels of CCL22 in women patients which represents that the reduction in CCL22 levels may play an important role in the pathogenesis of the disease in women. In women patients, the levels of CCL22 were influenced by disease pattern and treatment.
趋化因子在多发性硬化症（MS）等自身免疫性疾病中起着重要作用。性别也会影响 MS 的易感性和病程。本研究旨在探讨女性和男性 MS 患者血清中巨噬细胞来源趋化因子（CCL22）的水平。采集了 135 名健康受试者（35 名男性和 100 名女性）和 135 名 MS 患者（29 名男性和 136 名女性；47 名新诊断和 88 名治疗患者，其中有复发缓解型（RRMS；n=65）、继发进展型（SPMS；n=37）、原发进展型（PPMS；n=19）或进展复发型（PRMS；n=14））的血样。通过 ELISA 法测定 CCL22 的血清水平。新诊断的 MS 男性与健康男性的 CCL22 平均血清水平差异无统计学意义，但新诊断的 MS 女性的 CCL22 平均血清水平明显低于治疗后的 MS 女性和健康女性（P<0.006 和 P<0.0001）。不同治疗方案的男性患者的 CCL22 平均水平差异无统计学意义，但与未治疗的女性患者相比，接受干扰素-β或干扰素-β联合甲基强的松龙治疗的女性患者的 CCL22 平均水平明显升高（P<0.01 和 P<0.05）。RRMS 和 PRMS 模式的女性患者的 CCL22 水平也明显高于健康女性（P<0.05 和 P<0.01）。这些结果表明女性患者的 CCL22 水平较低，这表明 CCL22 水平的降低可能在女性疾病发病机制中发挥重要作用。在女性患者中，CCL22 水平受疾病模式和治疗的影响。
